Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1861-0714
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines ; day:9 ; month:2 ; year:2017 ; pages:1-6
Clinical research in cardiology supplements ; (9.2.2017), 1-6
- Keyword
-
Kardiovaskuläre Krankheit
- Contributor
-
Klingel, Reinhard
Heibges, Andreas
Fassbender, Cordula
SpringerLink (Online service)
- DOI
-
10.1007/s11789-017-0082-3
- URN
-
urn:nbn:de:1111-2017030513000
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Klingel, Reinhard
- Heibges, Andreas
- Fassbender, Cordula
- SpringerLink (Online service)
Other Objects (12)
Factors inducing cardiovascular events in patients treated by lipoprotein apheresis
Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease
Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment
Current Role of Lipoprotein Apheresis
Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels
Lipoprotein (a), an independent cardiovascular risk marker
Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels
Lipoprotein apheresis affects the concentration of extracellular vesicles in patients with elevated lipoprotein (a)
The German Lipoprotein Apheresis Registry (GLAR) – almost 5 years on
Lipoprotein(a) and Cardiovascular Disease Prevention across Diverse Populations
Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case report
Editorial Lp(a) – the underestimated cardiovascular risk factor
Factors inducing cardiovascular events in patients treated by lipoprotein apheresis
Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease
Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment
Current Role of Lipoprotein Apheresis
Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels
Lipoprotein (a), an independent cardiovascular risk marker
Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels
Lipoprotein apheresis affects the concentration of extracellular vesicles in patients with elevated lipoprotein (a)
The German Lipoprotein Apheresis Registry (GLAR) – almost 5 years on
Lipoprotein(a) and Cardiovascular Disease Prevention across Diverse Populations
Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case report
Editorial Lp(a) – the underestimated cardiovascular risk factor
Factors inducing cardiovascular events in patients treated by lipoprotein apheresis
Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease
Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment
Current Role of Lipoprotein Apheresis
Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels
Lipoprotein (a), an independent cardiovascular risk marker
Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels
Lipoprotein apheresis affects the concentration of extracellular vesicles in patients with elevated lipoprotein (a)
The German Lipoprotein Apheresis Registry (GLAR) – almost 5 years on
Lipoprotein(a) and Cardiovascular Disease Prevention across Diverse Populations
Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case report